Seattle Genetics is a biotechnology company, headquartered in Bothell, Washington, that has a primary focus on commercializing and developing antibody based therapies to treat cancer. They are known as an industry leader in developing antibody-drug conjugates, known as ADC’s. These drugs are powerful in the treatment of cancer as they can deliver cell-kiling agents directly to cancer cells. ADC’s are specifically designed to spare cells that are not cancerous, and thus, reduces many of the toxic effects of traditional cancer treatments. This is also in addition to the unique ability to potentially enhance anti-tumor activity. Seattle Genetics‘ success in the production of these drugs makes them a key alley in the fight against cancer.
The company was founded in 1997 and, to date, currently employs more than 650 individuals across the United States. In 2001, the company completed a public offering and began to be traded on the Nasdaq Stock Market under the symbol SGEN. Seattle Genetics’ CEO, Clay Siegall, is a scientist with extensive training that emphasizes different cancer treatments and drug therapies. Under his guidance, the company has entered into multiple strategic licenses for its ADC’s. A few of these licenses include,: Genentech (Roche), AbbVie, GlaxoSmithKline and Pfizer. These licenses, to date, have generated over $300 million. Prior to co-founding and managing Seattle Genetics, Dr. Clay Siegall worked for the Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute for several years. Dr. Siegall also contributes his knowledge to several other different agencies, including serving on the board of directors for: Ultragenyx Pharmaceutical, Alder BioPharmaceuticals, and Washington Roundtable.